FDA panel reviews peptide compounding

The U.S. FDA's Pharmacy Compounding Advisory Committee meets on July 23-24, 2026, to consider adding seven popular peptides (including BPC-157, TB-500, and Semax) to the 503A Bulks List, which would allow state-licensed compounding pharmacies to prepare them for patients with prescriptions. The review follows a 2023 FDA crackdown on compounded peptides and comes amid growing consumer demand fueled by social media, biohacking communities, and endorsement from Health Secretary Robert F. Kennedy Jr. FDA staff reviewers have cited limited evidence of safety and efficacy, while industry participants argue for regulated access. The panel's recommendation is advisory and non-binding.